Article
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer.
Science bulletin - 15 Jul 2024
Kong Lingping, Meng Fanlu, Zhou Ping, Ge Ruixin, Geng Xiaoshan, Yang Zhihao, Li Guo, Zhang Linlin, Wang Jing, Ma Jinfeng, Dong Cheng, Zhou Jun, Wu Sijin, Zhong Diansheng, Xie Songbo
Abstract excerpt
Targeting oncogenic mutant p53 represents an attractive strategy for cancer treatment due to the high frequency of gain-of-function mutations and ectopic expression in various cancer types. Despite extensive efforts, the absence of a druggable active site for small molecules has rendered these mutants therapeutically non-actionable. Here we develop a selective and effective proteolysis-targeting chimera (PROTAC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.